Aberrant expression of ADAM9 in ovarian cancer and its clinical significance.

BACKGROUND:The oncogene a disintegrin and metalloproteinase 9 (ADAM9) was up-regulated in ovarian cancer tissues, and the present study aims to explore the potential diagnostic and prognostic value of ADAM9 in ovarian cancer (OC). METHODS:A total of 30 paired fresh OC tumor tissues and the paired-adjacent normal tissue, and 90 formalin-fixed paraffin-embedded (FFPE) OC samples and adjacent normal tissue were collected. The expression of OC in FFPE samples was examined by immunohistochemical methods, and the mRNA expression of ADAM9 in fresh tumor samples was examined by RT-qPCR methods. Receiver operating characteristics curve was drawn to analyze the potential diagnostic value of ADAM9. Kaplan-Meier survival analysis was performed to compare the overall survival (OS) and disease-free survival (DFS) of the ADAM9 positive and negative OC patients. RESULTS:The positive rate of ADAM9 in FFPE OC tumor tissue was markedly higher than in the non-tumorous tissue (61/90 vs 47/90), and increased expression level of ADAM9 may associate with higher histological grade, advanced Figo stage and increased risk of metastasis; moreover, the mRNA expression of ADAM9 was also increased in OC tissue compared with the normal tissue (P < .001), and results of ROC analysis suggested that ADAM9 is a sensitive marker for the diagnosis of OC( AUC 0.8389, 95% confidence interval 0.7333 to 0.9445); finally, increased expression of ADAM9 may indicate decreased OS (P = .004) and DFS (P = .014) of the patients. CONCLUSION:A disintegrin and metalloproteinase 9 was up-regulated in OC, and ADAM9 may serve as potential diagnostic and prognostic marker for the diagnosis and treatment of OC.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}